ArticleCancers2021

Phase I Trial of Prophylactic Donor-Derived IL-2-Activated NK Cell Infusion after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Sibling Donor.

Raynier Devillier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.